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Abstract 
Background: Current human influenza vaccines lack the adaptability to match the mutational rate of the virus and 
therefore require annual revisions. Because of extensive manufacturing times and the possibility that antigenic altera-
tions occur during viral vaccine strain production, an inherent risk exists for antigenic mismatch between the new 
influenza vaccine and circulating viruses. Targeting more conserved antigens such as nucleoprotein (NP) could pro-
vide a more sustainable vaccination strategy by inducing long term and heterosubtypic protection against influenza. 
We previously demonstrated that intranodal mRNA injection can induce potent antigen-specific T-cell responses. 
In this study, we investigated whether intranodal administration of mRNA encoding NP can induce T-cell responses 
capable of protecting against a heterologous influenza virus challenge.
Methods: BALB/c mice were immunized in the inguinal lymph nodes with different vaccination regimens of mRNA 
encoding NP. Immune responses were compared with NP DNA vaccination via IFN-γ ELISPOT and in vivo cytotoxicity. 
For survival experiments, mice were prime-boost vaccinated with 17 µg NP mRNA and infected with 1LD50 of H1N1 
influenza virus 8 weeks after boost. Weight was monitored and viral titers, cytokines and immune cell populations in 
the bronchoalveolar lavage, and IFN-γ responses in the spleen were analyzed.
Results: Our results demonstrate that NP mRNA induces superior systemic T-cell responses against NP compared to 
classical DNA vaccination. These responses were sustained for several weeks even at low vaccine doses. Upon chal-
lenge infection, vaccination with NP mRNA resulted in reduced lung viral titers and improved recovery from infection. 
Finally, we show that vaccination with NP mRNA affects the immune response in infected lungs by lowering immune 
cell infiltration while increasing the fraction of T cells, monocytes and MHC  II+ alveolar macrophages within immune 
infiltrates. This change was associated with altered levels of both pro- and anti-inflammatory cytokines.
Conclusions: These findings suggest that intranodal vaccination with NP mRNA induces cross-strain immunity 
against influenza, but also highlight a paradox of influenza immunity, whereby robust immune responses can provide 
protection, but can also transiently exacerbate symptoms during infection.
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Background
The development of an influenza vaccine in the late 1940s 
can be considered as one of the great milestones in mod-
ern medicine. Currently licensed human influenza vac-
cines are very safe and likely prevent numerous deaths 
and hospitalizations [1]. In general, protection provided 
by conventional influenza vaccines depends upon the 
generation of neutralizing antibody responses against the 
viral hemagglutinin (HA) and, to some extent, antibod-
ies that can inhibit the viral neuraminidase (NA) activ-
ity. Such responses can effectively reduce or even prevent 
influenza and confer herd immunity on a population scale 
but are largely restricted to the strains included in the 
vaccine. Mismatches between the strains covered by the 
vaccine and the strains that are actually circulating can 
therefore result in a reduced, if not abolished, efficacy of 
the vaccine leading to an increased disease burden, and 
therewith associated a higher mortality, but also a signifi-
cant financial cost for companies and society [2, 3].
Influenza vaccine formulations require annual revi-
sions due to the relatively high mutational frequencies 
that occur within the major antigenic regions of HA and 
NA through the processes of antigenic drift [4]. This 
requirement, together with a significant production time 
of several months, forces vaccine manufacturers to rely 
on predictions of the strain that will most likely circulate 
in the next season, thereby running the risk of developing 
a mismatched vaccine [5].
For this reason, and, for influenza A, as a measure 
against a future pandemic influenza outbreak, the devel-
opment of a so-called universal vaccine that targets more 
conserved antigens, such as the nucleoprotein (NP), 
could provide a more sustainable approach by protect-
ing against multiple strains of influenza [6]. The presence 
of T cells that target conserved antigens, and are capable 
of lysing virus-infected cells, has been demonstrated to 
correlate with reduced disease and enhanced viral clear-
ance in influenza patients [7, 8]. In addition, pre-existing 
 CD8+ T-cell responses against NP have been shown to 
cross-react with multiple subtypes of influenza, high-
lighting the breadth of protection that could be achieved 
through T-cell based vaccines [9–12].
Several studies have established proof of concept for 
the development of a universal vaccine using gene-based 
strategies such as the use of DNA plasmids or viral vec-
tors. However, such delivery methods still have impor-
tant drawbacks regarding safety and clinical efficacy. In 
contrast, mRNA-based gene delivery strategies offer a 
more favorable safety profile as exogenous mRNA is only 
transiently present in the cytosol and thus unlikely to 
incorporate into host genes [13]. In addition, mRNA pos-
sesses an intrinsic adjuvant activity that can activate toll-
like receptors (TLRs) and RIG-I-like receptors (RLRs) 
[14]. Therefore, mRNA could provide an attractive plat-
form for the development of a universal vaccine against 
influenza.
Previously, we have shown that intranodally delivered 
naked mRNA is almost exclusively taken up and trans-
lated by dendritic cells (DCs) [15]. DCs play a crucial role 
in T-cell activation through antigen-presentation and by 
providing immunostimulatory signals. Uptake of tumor 
antigen-encoding mRNA by these DCs resulted in robust 
T-cell responses that delayed tumor growth in mice.
Furthermore, intranodal vaccination was shown to 
allow for lower vaccine doses while maintaining the same 
immunogenicity as other administration routes [16–18]. 
Therefore, intranodal vaccination provides an attractive 
method for mRNA vaccines.
In this study, we evaluated whether intranodally deliv-
ered naked mRNA can elicit robust T-cell responses 
against the conserved antigen NP of an H3N2 influenza 
strain and compared these responses to those obtained 
through DNA vaccination.
Materials and methods
Animals
Specific pathogen-free female 6  week old BALB/c mice 
were purchased from Charles River, housed in indi-
vidually ventilated cages and handled according to the 
guidelines and regulations of the animal care committee 
of the Vrije Universiteit Brussel (VUB, License number 
LA1230214, ethicom nr. 16-214-10 and institutional Eth-
ics Committee on experimental animals of the Vlaams 
instituut voor Biotechnology (VIB, License Number 
LA1400536, ethicom nr.EC2014-076).
In vitro transcription of mRNA vaccines
The sequence for NP was derived from the influenza A/
NL/18/94 H3N2 nucleoprotein as described previously 
[19]. The NP sequence was cloned in-frame between the 
murine signal sequence of the murine LAMP-1 protein 
and the human transmembrane and cytoplasmic domains 
of human DC-LAMP, a subcellular targeting strategy to 
enhance presentation in both MHC I and MHC II class 
pathways [20, 21]. The sequence of hemagglutinin (HA) 
was derived from influenza A/PR/8/34 H1N1. Both HA 
and NP sequences were further cloned into the pEth-
eRNA vector (eTheRNA immunotherapies) containing 
a 5′ end translation enhancer and 3′ end RNA stabiliza-
tion sequence. Truncated nerve growth factor (tNGFR) 
mRNA was produced as previously described [22].
The mRNA was then produced as described [15] and 
resuspended in 10 µl total volume per injection contain-
ing 2 µl endotoxin free water and 8 µl Hartmann (Baxter) 
solution following immunization.
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DNA plasmid preparation
The NP sequence from A/NL/18/94 H3N2 was cloned 
into the pCAXL plasmid vector and sequence veri-
fied [23]. LPS-free plasmid DNA vaccines were 
prepared following the manufacturer instructions 
(EndoFree Plasmid Kit, Qiagen). Endotoxin levels were 
subsequently determined using the Genscript Toxin-
SensorTM Chromogenic LAL Endotoxin Assay Kit.
Immunizations
Intranodal immunizations with mRNA were per-
formed by surgically exposing the inguinal lymph node 
of anaesthetized animals followed by the injection of 
the indicated amounts of mRNA in a total volume of 
10  µl. Incision wounds were subsequently closed and 
disinfected. Repeated immunizations were alternated 
between the left and right inguinal lymph nodes. Mice 
in the control group received mRNA encoding tNGFR 
as previously described [15].
DNA vaccines were diluted in buffered saline to a 
concentration of 1  mg/ml and injected in the quadri-
ceps muscles of the hind legs (50 µl/leg) of anesthetized 
mice.
Viral challenges
Mice were sedated with isoflurane and infected intra-
nasally with  1LD50 of influenza A Puerto Rico/8/1934 
H1N1 (PR8). Body weight was monitored each day for 
2  weeks. At 75% of the initial body weight, mice were 
sacrificed by cervical dislocation.
Bronchoalveolar lavage
Bronchoalveolar lavage fluids (BALF) were isolated 
as described [24]. Mice were anesthetized and a small 
incision was made in the trachea to insert a lavage can-
nula in the trachea. Lungs were lavaged four times with 
1 ml of HBSS with 0.05 mmol/l EDTA (Sigma-Aldrich). 
The first lavage fluid was used to determine cytokine 
levels. The BAL fluid was separated from the BAL cell 
pellet by centrifugation (7 min; 400g; 4 °C).
Plaque assay
Tenfold serial dilution sera of BALF were added to a 
monolayer of MDCK cells in 6-well plates. MDCK were 
cultured in serum free OptiMEM medium (Invitro-
gen) supplemented with penicillin and streptomycin. 
After 1 h at 37 °C, serum free medium containing 0.6% 
avicel RC-851 (FMC Biopolymers) and trypsin was 
added to the cells for 3  days at 37  °C. After infection, 
cells were washed with PBS and subsequently fixed in 
4% paraformaldehyde for 30  min at 37  °C. Plates were 
then washed with PBS and blocked for 1 h with 1% BSA 
and 0.05% Tween20 in PBS. To stain the viral plaques, 
convalescent anti-PR8 mouse serum was added for 1 h. 
After washing three times with 1% BSA in PBS, wells 
were incubated with HRP-conjugated anti-mouse IgG 
antibodies (Southern Biotech) for 1  h. Non-binding 
antibodies were removed by two washing steps with 
PBS containing 1% BSA and 0.05% Tween20 and one 
wash with PBS. Finally, TrueBlue peroxidase substrate 
(KPL, Gaithersburg) was added to visualize the plaques. 
The plaques of at least two different dilutions were 
counted and for each dilution, the number of PFU were 
calculated by multi-plying the number of plaques pre-
sent at the given dilution with the corresponding dilu-
tion factor and expressed as the number of PFU/1  ml 
BAL fluid.
IFN‑γ ELISPOT
Isolated splenocytes were stimulated at 4  ×  105 cells 
per well (Multiscreen-IP PVDF Filter plates, Milipore) 
for 20 h with 5 µg/ml of peptides (Eurogentec). The NP 
peptide (147–155) is the cross-reactive H-2Kd-restricted 
epitope derived from the influenza A H1N1 PR8 virus 
comprising the amino acid sequence TYQRTRALV and 
is sequence identical between influenza A H1N1 PR8 and 
influenza A/NL/18/94 H3N2. This peptide was shown 
to constitute the immunodominant epitope of NP in 
BALB/c mice [25].
The HA peptide (518–526) is a H-2Kd-restricted 
epitope derived from the influenza A H1N1 PR8 virus 
comprising the amino acid sequence IYSTVASSL. For 
intra-assay negative and positive controls, medium 
(Mock) or Dynabeads Mouse T-Activator CD3/CD28 
beads (Thermofisher, data not shown) were used, respec-
tively. IFN-γ detection was performed using the murine 
IFN-γ ELISPOT kit from Diaclone. Spot forming cells 
(SFC) were counted using an ELISPOT reader (Autoim-
mun Diagnostika GmbH, Germany) and are shown after 
background (mock conditions) subtraction.
In vivo cytotoxicity assay
The in  vivo cytotoxicity was performed as previously 
described [26]. Splenocytes isolated from naïve BALB/c 
mice were used as target cells and pulsed for 90  min at 
37  °C with 5  µg/ml of peptides before labelling the cells 
with 1.5 µM of CellTrace Violet (CTV, Thermofischer Sci-
entific) according to the manufacturer’s protocol. Labeled, 
peptide-pulsed target cells were then mixed in a 1:1 ratio 
with non-pulsed splenocytes from naïve BALB/c mice 
labelled with 0.15 µM CTV according to the manufacturer’s 
protocol. The splenocyte mix was then resuspended in PBS 
and 1.5–2 ×  107 splenocytes were injected intravenously 
per animal. Lysis of target cells was analyzed 18 h later by 
flowcytometry of splenocytes isolated from the receiver 
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mice (LSR Fortessa, Beckton Dickinson). Vehicle injected 
mice were used as a background control (non-immunized). 
Specific lysis was calculated as follows:
Differential BAL cell counts
Flow cytometry was used to determine the number and 
types of cells present in the BAL fluid. Fc-blocked (1 µg/
ml; eBiosciences) BAL cells were stained with anti-mouse 
SiglecF-phycoerythrin (PE; 1  µg/ml; BD Pharmingen), 
CD45- allophycocyanin (APC; 1  µg/ml; eBiosciences), 
CD3-PECy5 (1 µg/ml; eBiosciences), CD19-PECy5 (1 µg/
ml; eBiosciences), CD11c-PECy7 (1 µg/ml; eBiosciences), 
MHCII-APC-efluor780 (1 µg/ml; eBiosciences), CD11b-
V450 (1  µg/ml; BD Pharmingen), Ly6C-FITC 1  µg/
ml; BD Pharmingen) and Ly6G-AlexaFluor700 (1  µg/
ml; BD Pharmingen). Fixable Viability Dye  eFluor® 506 
(eBiosciences) was added to exclude dead cells from the 
analysis.
Luminex
Undiluted isolated BAL samples were mixed with a 10% 
BSA solution to obtain a final concentration of 0.5% BSA 
per sample. The assay was further performed according 
to the manufacturer’s instruction (Bio-Plex PRO™ Mouse 
cytokine 23-plex Assay, Bio-Rad) and samples were ana-
lyzed in duplicates on a Bio-Plex 200 system (Bio-Rad).
Statistical analysis
Statistical analysis was performed using Graphpad Prism 
software version 6.00. Data was first analyzed for normal 
distribution using the Kolmogorov–Smirnov test. For 
normally distributed data, the unpaired two-tailed Stu-
dent’s t test and one-way ANOVA test with Bonferroni 
correction were used for pairwise or multiple compari-
sons. In case of non-normally distributed data or small 
sample sizes, the non-parametric Mann–Whitney test 
was used for pairwise comparisons. For all analyses, the 
minimal level of significance was set at P < 0.05 (*).
Results
Intranodal immunization with mRNA induces stronger 
T‑cell responses compared to intramuscular DNA 
vaccination
Vaccination with DNA encoding conserved influenza 
antigens has been studied extensively and was shown to 
induce cross-protective immunity in small animals [27]. 
To assess the capability of intranodally administered 
mRNA to induce cytotoxic T-cell responses, we com-
pared this vaccination method with the frequently used 
method of intramuscular DNA immunization. To this 
100×
[
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%CTVhigh/% CTVlow
)
immunized
/(
% CTVhigh/% CTVlow
)
non−immunized
)]
.
end, 50 µg of mRNA encoding NP derived from influenza 
A H3N2 or 100  µg of DNA encoding the same antigen 
were injected intranodally or intramuscularly, respec-
tively. Immunizations were given every 2  weeks for a 
total of 3 immunizations (Fig. 1a).
In mice that received intranodal NP mRNA injec-
tions, a significant increase in the ability to lyse antigen-
loaded target cells in lymph nodes and spleens compared 
to animals immunized intramuscularly with DNA was 
observed (Fig. 1b, c). Consistent with this finding, spleno-
cytes from mRNA vaccinated mice showed significantly 
higher numbers of IFN-γ producing T cells specific for 
NP compared to DNA NP animals (Fig. 1d).
These data demonstrate that intranodal immuniza-
tion with NP mRNA induces systemic T-cell responses 
against NP which are more potent than those induced by 
intramuscular DNA vaccination.
Intranodal immunization with a low‑dose mRNA vaccine 
induces prolonged T‑cell responses against NP
To further investigate the efficiency of intranodal mRNA 
vaccination, we evaluated whether we could lower the 
administered dose and reduce the number of immuni-
zations. To this end, mice were immunized according to 
several immunization schedules with varying doses of 
NP mRNA (Fig. 2a–c). A single immunization with 50 µg 
of NP mRNA induced cytotoxic T-cell responses in both 
lymph nodes and, to a lesser extent, the spleen (Fig. 2a), 
but analysis of these responses suggests that they were 
less potent compared to the results obtained from tri-
ple immunization with 50 µg NP mRNA in the previous 
experiment. In comparison, analysis of cytotoxic T-cell 
responses after vaccination with 50  µg of NP mRNA 
and 2  weeks between immunizations suggests that this 
prime-boost schedule improves targeted T-cell responses 
(Fig.  2b). Furthermore, the data also shows that T-cell 
responses in the spleen were higher than those in the 
lymph nodes, demonstrating that this schedule induces 
better systemic immunity.
Next, we assessed whether we could lower the admin-
istered dose of mRNA. To this end, mice were injected 
intranodally with 17  µg of NP mRNA according to a 
prime-boost schedule (schedule 3). Instead of a 2-week 
interval between immunizations, we shortened the 
time to 1  week as shorter time-intervals were shown to 
improve T-cell responses [28]. Analysis of cytotoxic T-cell 
responses in lymph nodes and spleens after this immuni-
zation schedule suggests that these were comparable to 
those achieved through prime-boost immunization with 
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50 µg NP mRNA (schedule 2), though the data suggests a 
higher variation between animals (Fig. 2c).
We further evaluated the potency of this vaccina-
tion schedule (schedule 3) by investigating the dura-
tion of active T-cell responses and found that cytotoxic 
T-cell responses capable of lysing antigen-pulsed target 
cells were still elevated 21 days after booster immuniza-
tion in both lymph nodes and spleen (Fig. 2d). Although 
cytolytic responses were significantly reduced on day 28, 
ELISPOT analysis demonstrated the persistence of IFN-γ 
producing T cells in the spleen at this timepoint. On day 
49, both cytolytic and IFN-γ T-cell responses subsided.
Together, these data demonstrate that intranodal 
prime-boost immunization with a low-dose mRNA vac-
cine induces robust and prolonged T-cell responses 
against NP.
Intranodal immunization with NP mRNA results in viral 
clearance and modest protection against a heterologous 
challenge
Next, we evaluated whether intranodally administered 
mRNA encoding NP could protect mice from a lethal 
challenge with a heterologous strain of influenza. Mice 
were immunized twice with 17 µg of NP mRNA or con-
trol mRNA and infected 8  weeks later with influenza 
A H1N1 PR8. As a positive control, we included mice 
immunized with mRNA encoding PR8 HA. Both NP 
and HA vaccinated animals showed significantly lower 
viral titers within the lungs on day 6 after challenge com-
pared to control animals (Fig. 3a). However, both HA and 
NP vaccinated animals experienced temporary weight 
loss, which was more pronounced in the NP conditions 
(Fig.  3b). Compared to control animals, NP vaccinated 
mice showed a trend towards greater weight loss from 
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Fig. 1 Comparison of T-cell responses after intranodal immunization with NP mRNA or intramuscular immunization with NP DNA. a BALB/c mice 
were immunized every 2 weeks for a total of three immunizations with 50 µg of intranodally delivered mRNA encoding NP, 100 µg intramuscularly 
delivered DNA encoding NP or 0.8 RL intranodally (vehicle). Analysis of in vivo cytotoxic T-cell responses (b, c) and ex vivo IFN-γ production (d) 
was assessed 4 days after the last immunization. b, c In vivo antigen-specific lysis of CellTrace Violet (CTV)-labelled NP peptide-loaded target 
cells was assessed in lymph nodes (b) and spleens (c). Histograms show the lysis of target cells and are representative for each group. d Ex vivo 
IFN-γ responses assessed by ELISPOT from splenocytes isolated from vaccinated animals and re-stimulated with NP peptide. Results from each 
experiment are shown as median ± interquartile range (IQR) with each symbol representing one mouse for a total of 4–8 mice per experiment. 
Differences between groups were analyzed by Mann–Whitney U test (b), Student’s t test (c), or one-way ANOVA (d)
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Fig. 2 Evaluation of different immunization schedules and duration of T-cell responses after vaccination with NP mRNA. a–c BALB/c mice were 
immunized according to different vaccination schedules with varying amounts of mRNA NP. In vivo antigen-specific lysis of NP peptide-loaded 
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were analyzed by Kruskal–Wallis test with Bonferroni correction
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day 4 to day 8, but their weight recovered faster after day 
8. In total, 40% of control mice succumbed to the infec-
tion compared to 20% of NP vaccinated mice (Fig.  3c). 
These data show that intranodal immunization with NP 
mRNA contributes to viral clearance, but provides only 
modest protection against heterologous H1N1 infection.
Analysis of immune cell infiltrates in spleen and BALF 
of vaccinated animals
As intranodal vaccination with NP encoding mRNA 
resulted in modest protection against influenza A virus 
challenge and a temporary increase in weight loss com-
pared to control mice, we performed additional immune 
analyses to identify the underlying mechanisms.
First, we assessed whether infection by H1N1 results in 
re-activation of systemic antigen-specific T-cell responses 
in vaccinated animals. To this end, IFN-γ ELISPOT anal-
ysis was performed on the spleens of vaccinated animals 
on day 6 after infection. Consistent with the previous 
results, we found significantly higher responses against 
NP in NP mRNA vaccinated animals, compared to HA 
and control vaccinated animals, although responses 
against NP were also found in the latter groups (Fig. 4a). 
Furthermore, HA immunized animals did not induce 
robust IFN-γ T-cell responses against HA peptide. HA-
peptide responses were also undetectable in NP immu-
nized or control vaccinated animals. These results are 
consistent with NP being an immunodominant target for 
 CD8+ T-cell responses and demonstrate that intranodal 
immunization with NP induces T-cell responses which 
are re-activated upon heterologous infection.
As we found a reduction in lung viral titers, we inves-
tigated the composition of the immune cell infiltrate in 
the BALF of vaccinated animals on day 6 after infection. 
Flow cytometry was used to distinguish T cells, DCs, 
monocytes, eosinophils, neutrophils and alveolar mac-
rophages (AMs) in the BALF (see Additional file 1: Fig-
ure S1). While NP and HA mice had similar numbers of 
 CD45+ cells in the BALF, the BALF of control animals 
contained a more than tenfold higher number of these 
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cells (Fig.  4b). In line with this result, we found signifi-
cantly higher numbers of T cells, DCs,  Ly6C− monocytes, 
eosinophils, neutrophils and AMs, but not  Ly6C+ mono-
cytes, in the BALF of control animals (Fig. 4c).
However, analysis of the relative composition of infil-
trating  CD45+ cells revealed a more nuanced image 
between groups (Fig.  4d). Mice vaccinated with NP 
mRNA showed an increased percentage of T cells within 
the  CD45+ population compared to the control group 
(Fig. 4e). In the HA group, increased percentages of DCs 
were found compared to control mice (Fig. 4f ). Both NP 
and HA vaccinated animals also showed significantly 
increased percentages of  Ly6C−  and  Ly6C+ monocytes 
compared to controls (Fig. 4g, h).
As AMs can contribute to T-cell responses through 
antigen presentation, we also assessed the expression 
of MHC II on this subset. Although no differences were 
found in the percentages of the overall AM populations 
in the BALF, for both NP and HA animals an increase in 
the percentage of AMs expressing MHC II was observed 
(Fig. 4l). No significant increases were found for the per-
centage of eosinophils and neutrophils between groups, 
though control group animals displayed increased popu-
lations within the granulocyte gate which were neither 
eosinophils or neutrophils (included in the ‘Other’ group 
in Fig. 4d, data not shown).
To summarize, these data show that NP vaccination 
induces systemic T-cell responses which can be re-acti-
vated and are present in the lungs during heterologous 
infection. In addition, NP vaccination results in lower 
numbers of infiltrating immune cells in the BALF and 
also affects the composition of innate cells.
Analysis of cytokines in the BALF of vaccinated animals
To further explore the differences observed by flow 
cytometry, we evaluated the inflammatory cytokine pro-
files in the lungs of vaccinated animals.
Of the 23 cytokines and chemokines that were ana-
lyzed by Luminex assay (see Additional file 2: Table S1), 
significantly higher concentrations were observed for 
the proinflammatory factors IFN-γ, IL-2, MIP-1α/CCL3, 
MIP-1β/CCL4, IL-9, IL-13 and the anti-inflammatory 
cytokine IL-10 for NP vaccinated animals on day 6 after 
infection compared to control animals (Fig.  5). In addi-
tion, a strong trend towards higher concentrations of 
IL-6 was observed. Compared to HA recipients, NP vac-
cinated animals showed elevated levels of IFN-γ, IL-2, 
IL-9 and G-CSF. In contrast, increased concentrations of 
IL-17A and IL-12p40 were found in the BALF of control 
mice.
These results show that upon infection, intranodal vac-
cination with NP mRNA enhances the production of a 
distinct cytokine profile, which mostly bears a proinflam-
matory signature.
Discussion
In this study, we show that intranodal injection of a low 
dose naked mRNA vaccine encoding influenza NP elic-
its robust T-cell responses and is capable of protecting 
mice against heterologous infection. Although initially a 
slightly enhanced weight loss was observed, NP mRNA 
vaccinated recipients recovered faster from infection.
Nucleic acid vaccines represent a promising strategy 
against pathogens owing to their versatility in encoding 
any protein or antigen of choice. In addition, such vac-
cines can be manufactured using the same materials and 
processes irrespective of the encoded protein, providing 
the potential for rapid and flexible vaccine production 
and economies of scale [29]. Despite these benefits, DNA 
vaccines have important safety concerns such as the long-
term presence and expression of plasmid DNA, albeit at 
low levels [30]. Furthermore, low levels of plasmid inte-
gration into the host’s genome have been detected, har-
boring the risk of insertional mutagenesis [31, 32]. In 
contrast, mRNA does not enter the nucleus and therefore 
does not integrate into DNA by itself [33, 34]. As mRNA 
does not need to pass the nuclear membrane, its transla-
tion is almost immediate upon cytosol entry and is also 
efficient in non-dividing cells [35, 36]. Importantly, the 
expression of mRNA is also transient which limits the 
risk of toxicity [37].
Fig. 4 Analysis of systemic responses and immune cell populations in the BALF after H1N1 challenge. BALB/c mice were immunized twice 
with 17 µg of NP or control mRNA (Ctrl) or 50 µg of HA mRNA with 1 week between immunizations. 8 weeks after boost immunizations, mice 
(n = 6/group) were infected with 1xLD50 of influenza A H1N1 PR8. On day 6 after challenge, spleens and BALF were isolated. a IFN-γ ELISPOT 
on splenocytes isolated from vaccinated animals on day 6 after challenge and re-stimulated with the indicated peptides. Images of wells are 
representative for all mice for the respective conditions. b–l Flow cytometric analysis of immune cell populations within the BALF. AM, Alveolar 
macrophages. b Absolute cell count of  CD45+ cells. c Absolute cell count of  CD45+ subsets. d Donut-charts showing the composition of  CD45+ 
subsets per group. Fractions show the median of the indicated subpopulations. The number in the center shows the median number of  CD45+ 
cells for that group. e–k Percentages of  CD45+ subsets within the  CD45+ population. l Percentage of MHC II expressing AM within the general AM 
population. For all graphs, except donut-charts, results are shown as median ± IQR and each symbol represents one mouse for a total of 6 mice per 
group. Differences between groups were calculated using one-way ANOVA
(See figure on previous page.)
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Our group previously reported that intranodal immu-
nization using naked mRNA induces strong primary 
T-cell responses and memory formation in mice [15, 
38]. Consistent with these data, intranodal immuniza-
tion with mRNA encoding NP derived from influenza 
A H3N2 induced strong and systemic T-cell responses 
which remained active for several weeks before sub-
siding, even at low doses of the vaccine. Furthermore, 
responses induced through this method proved to be 
superior compared to those induced by intramuscular 
DNA vaccination.
Several groups have demonstrated the induction of 
T-cell responses and protective efficacy after intramuscu-
lar vaccination with DNA NP in preclinical studies [27, 
39–45]. We therefore wanted to use this well-established 
model for nucleotide vaccination to benchmark our 
intranodal mRNA vaccine approach. While the purpose 
of this study was not to extensively compare both vac-
cination methods, two factors could explain our results. 
First, the intranodal delivery route has been shown to 
be superior for both mRNA and DNA methods in elic-
iting antigen-specific T-cell responses [15, 16, 46]. In 
this regard, intranodal DNA immunization allowed for 
a 100-fold lower vaccine dose while maintaining similar 
 CD8+ T-cell responses compared to intramuscular deliv-
ery [16]. Another potential factor is the immunogenic-
ity of the molecules. Though DNA has shown potential 
in preclinical models, the translation of these results into 
humans has been challenging in terms of achieving suf-
ficient immunogenicity [47]. In this regard, mRNA has 
been shown to possess intrinsic adjuvant activity which 
facilitates the induction of adaptive responses [46] via the 
triggering of different RNA sensors and type I IFN induc-
tion [48, 49]. Indeed, intratumoral delivery of ‘control’ 
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Fig. 5 Analysis of cytokines in the BALF of vaccinated animals after H1N1 challenge. BALB/c mice were immunized twice with 17 µg of NP or 
control mRNA (Ctrl) or 50 µg of HA mRNA with 1 week between immunizations. 8 weeks after boost immunizations, mice were infected with 
1xLD50 of influenza A H1N1 PR8. BALF was isolated on day 6 after challenge and cytokines were analyzed using Luminex. Graphs depict the 
concentration of the indicated cytokines as median ± IQR with each symbol representing one mouse. n = 6 for NP and HA groups, n = 5 for Ctrl 
group. Differences between groups were calculated using one-way ANOVA
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mRNA encoding irrelevant antigens was shown to reduce 
tumor growth by itself [50].
It is important to note, however, that DNA also acti-
vates immunostimulatory pathways via pathogen recog-
nition receptors including TLR9 [51], TBK1 [52], AIM2 
[53] and the cGAS-STING pathway [54].
Upon intranodal vaccination, the effector T-cell 
response was sustained for several weeks before sub-
siding. Though, the duration and quality of a vaccine-
induced immune response is dependent on many 
factors including the antigen, early studies in acute 
lymphocytic choriomeningitis virus (LCMV) infection 
revealed that the peak of the T-cell response occurs 
at day 8 post-infection followed by the contraction 
phase during which 90% of T cells die by day 21 [55]. 
In a tumor mouse model, T-cell responses induced 
by intranodal mRNA vaccination were almost fully 
contracted around day 24 [38]. In contrast, we still 
observed elevated IFN-γ producing T cell responses in 
the spleen at 28  days after the last immunization sug-
gesting that the effector T-cell response had not yet 
fully contracted.
Upon heterologous H1N1 infection, these responses 
were systemically re-activated as we found increased 
IFN-γ + T-cell responses in the spleens of NP vaccinated 
animals. However, splenic  CD8+ T cells were shown to be 
negligible for protection whereas T-cell responses in the 
lungs were crucial for live-attenuated influenza vaccine-
induced protection [56]. It is therefore unclear to which 
extent these systemic responses contributed to protec-
tion which could explain the relatively modest protection 
against influenza A virus challenge infection.
Nevertheless, NP mRNA vaccination lowered lung 
viral titers which is consistent with earlier reports from 
our group that intranodal mRNA can establish mucosal 
T-cell responses in the lungs [38]. Consistent with the 
notion that T-cell based vaccines clear infected cells but 
do not completely prevent disease symptoms [57, 58], 
we found that NP vaccinated mice initially experienced 
a greater weight loss after infection compared to control 
animals.
Immunopathology from excessive inflammation has 
been widely described in the pathology of influenza, 
suggesting that protective immunity is a fine balance 
between offense and restraint. In this regard,  CD8+ 
T-cell responses capable of killing infected cells can sig-
nificantly enhance viral clearance and speed up recovery, 
but can also contribute to destructive lung inflamma-
tion when left unchecked [57, 59]. This phenomenon 
was demonstrated in a T-cell deficient mouse model in 
which infection with influenza resulted in slower disease 
progression and lung pathology compared to wildtype 
mice. However, progression lasted much longer due to 
sustained viral replication ultimately leading to signifi-
cantly lower survival of T-cell deficient mice [60]. In line 
with these studies, we observed that mice vaccinated 
with NP mRNA initially experienced greater weight loss, 
but a faster recovery later on. Analysis of the BALF of NP 
vaccinated mice showed a larger representation of T cells 
and monocytes within the  CD45+ population compared 
to control animals. Strikingly, however, control mice dis-
played significantly higher absolute numbers of leuko-
cytes within the BALF which has previously correlated 
with unchecked inflammation and disease progression 
in influenza [61, 62]. Although NP vaccinated mice had 
lower total T-cell numbers in the BALF compared with 
challenged control mRNA vaccinated mice, these T cells 
seemed to be more potent in viral clearance.
Ly6C− monocytes are considered anti-inflammatory 
and play a role in tissue repair, but have been shown to 
contribute to early inflammation and attraction of neu-
trophils [63]. In contrast,  Ly6C+  monocytes induce 
a more pronounced inflammatory response through 
cytokine secretion and contribute to pathogen clearance 
via phagocytosis. Interestingly of all cell types analyzed, 
only  Ly6C+ monocytes were present in equal numbers in 
both NP, HA and control groups. Considering that mono-
cytes are a major target for influenza [64] and undergo 
apoptosis after infection [65], it is possible that the lack 
of viral control resulted in increased cell death and thus 
lower numbers within the BALF of challenged control 
mRNA vaccinated mice. Although we found no studies 
investigating the preference of influenza to target  Ly6C+ 
over  Ly6C− monocytes, it was shown that IL-17 modu-
lates the transition of  Ly6C+ to  Ly6C− monocytes [66]. 
This could explain why  Ly6C− monocytes were overrep-
resented in control mice compared to  Ly6C+ subsets.
Despite lower leukocyte recruitment, NP vaccinated 
mice showed elevated concentrations of proinflammatory 
cytokines within the lungs, indicating enhanced immune 
cell activation and inflammation compared to control 
animals. Though certain cytokines have been correlated 
with protection [67], their exact roles remain to be fully 
elucidated [68]. Furthermore, high levels of inflammatory 
cytokines have previously been directly correlated with 
symptom scores in infected patients and could there-
fore explain the initial weight loss [69, 70]. Hence, more 
research will be needed to understand the context-spe-
cific roles of cytokines during influenza infection.
An important caveat of interpreting these results is the 
lack of mRNA studies utilizing NP as a vaccine antigen 
against influenza. Petsch et  al. demonstrated that intra-
dermal administration of protamine-complexed mRNA 
encoding NP induced T-cell-dependent heterologous 
protection against influenza with a lower loss of weight 
compared to our study [71]. While no data was provided 
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on cytokines or infiltrating immune cell populations in 
this study, we can hypothesize that this vaccination strat-
egy was associated with a lower T-cell induced immu-
nopathology. This is based on previous research by our 
group which showed that intradermal immunization with 
mRNA leads to lower T-cell responses compared to the 
intranodal route [15].
Compared to this study, we used shorter time inter-
vals between immunizations as it has been suggested 
that short frequency immunizations can improve vaccine 
responses [72, 73]. In this regard, the speed of achieving 
adequate immunity could be crucial during outbreaks 
when time is of the essence. We were also able to use 
lower doses of mRNA which was likely facilitated by 
using the intranodal route [16].
Though less practical than intramuscular vaccines, 
intranodal vaccination provides the potential for lower 
vaccine doses while maintaining immunogenicity and 
allows for ‘naked’ mRNA delivery without packaging. In 
a clinical setting, intranodal mRNA delivery can be car-
ried out via ultrasound-guided syringe injections in the 
inguinal lymph nodes, which was demonstrated to be safe 
and immunogenic in a phase I mRNA vaccine study for 
HIV [74]. Importantly, intranodal delivery of personalized 
mRNA vaccines significantly reduced metastatic events 
and was associated with sustained progression-free survival 
in melanoma patients [75]. In the context of an universal 
vaccine against influenza, the more labor-intensive process 
of intranodal vaccination could be justified as an ideal uni-
versal vaccine provides protection against multiple influ-
enza strains for multiple seasons. In this regard, our results 
show that, in mice, potent T-cell responses can be induced, 
which remain active for several weeks before subsiding and 
are reactivated upon infection, indicating T-cell memory. 
Compared to the study by Petsch et al, the time between 
the last immunization and viral challenge was longer in our 
setting due to the length of active T-cell responses. How-
ever, further research must be conducted to improve pro-
tection and prevent the initial loss of weight by vaccination.
Conclusion
In conclusion, intranodal immunization with mRNA 
encoding NP induces strong T-cell responses capable of 
heterologous viral clearance within the lungs and improv-
ing recovery from infection. However, this response does 
result in a more pronounced, but transient, weight loss 
which occurs early on during infection most likely due 
to exaggerated inflammation. In this regard, T cells are 
a powerful target for broadly protective responses but 
must be balanced in order to avoid enhanced disease pro-
gression through pulmonary injury. The data provided in 
this report help to support the resolution of this paradox 
and pave the way towards a universal influenza vaccine.
Additional files
Additional file 1: Figure S1. Gating strategy for the flow cytometric 
analysis of  CD45+ subsets within the BALF. Debris and doublets were first 
excluded based on forward scatter (FSC) and sideward scatter (SSC). Dead 
cells were then excluded based on positivity for the viability dye following 
the identification of  CD45+ cells through staining. A sequential gating 
strategy was then used to identify T cells, B cells, alveolar macrophages 
(AM), dendritic cells (DC), neutrophils, eosinophils and  Ly6C+ and  Ly6C− 
monocytes according to the markers described in Additional file 2: 
Table S1. T cells and B cells were first isolated based on positivity for CD3 
or CD19 and negativity for CD11c. As these antibodies were conjugated 
with the same fluorochrome, T cells and B cells were further distinguished 
based on negative for MHC II or positive for MHC II, respectively. AM were 
then isolated based on high expression of Siglec F and CD11c. MHC  II+ 
AM were then isolated within the AM population based on MHC II expres-
sion. Next, DCs were isolated based on expression of CD11c and MHC II. 
MHC II negative cells were further distinguished using SSC-A into granulo-
cyte (SSC-A high) or monocyte (SSC-A low) subsets. Within the granu-
locyte gate, eosinophils were separated based on expression of Siglec 
F and high expression of CD11b. Neutrophils were distinguished based 
on high expression of CD11b, Siglec F negativity and Ly6G positivity. For 
monocytes, absence of Siglec F and Ly6G was first confirmed, following 
the separation of monocyte subsets based on the presence of Ly6C. 
Additional file 2: Table S1. Concentrations of cytokines within the BALF 
of vaccinated animals infected with H1N1 PR8 influenza. Values show 
the median concentration (pg/ml) with interquartile range (Q1–Q3) of 
the indicated cytokine or chemokine for the respective group. ND, not 
detected.
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